Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study)
- 1 June 2006
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 97 (11), 1553-1557
- https://doi.org/10.1016/j.amjcard.2005.12.042
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Progression of Subclinical Coronary AtherosclerosisCirculation, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Inflammation, insulin resistance, and obesityCurrent Atherosclerosis Reports, 2004
- Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary AtherosclerosisJAMA, 2004
- New paradigms in neuroendocrinology: Relationships between obesity, systemic inflammation and the neuroendocrine systemJournal of Endocrinological Investigation, 2004
- Antioxidant effects of statinsDrugs of Today, 2004
- Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory PathwaysCirculation, 2003
- Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin TherapyJAMA, 2003
- Approach to lipoprotein management in 2001 National Cholesterol GuidelinesThe American Journal of Cardiology, 2002
- Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARα/RXRα and Decrease the Transactivation of NFκBBiochemical and Biophysical Research Communications, 2002